FDA Expands Use of First Sickle Cell Disease Gene Therapy for Children as Young as 2 Years

WEDNESDAY, July 8, 2026-- The U.S. Food and Drug Administration has issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive...